(E)-3-(4-aminomethylphenyl)acrylic acid ethyl ester | 792185-51-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(4-aminomethylphenyl)acrylic acid ethyl ester
• 英文别名: ethyl (E)-3-(4-(aminomethyl)phenyl)acrylate；Ethyl 3-(4-(aminomethyl)phenyl)acrylate；ethyl (E)-3-[4-(aminomethyl)phenyl]prop-2-enoate
• CAS: 792185-51-4
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: POZPKRUDKZLIST-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-3-(4-aminomethylphenyl)acrylic acid ethyl ester 在 羟胺 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.07h， 生成 (4,4-dimethyl-3,4-dihydrocarbostyril)-6-carboxylic acid (E)-4-[2-(hydroxycarbamoyl)vinyl]benzylamide
  参考文献：
  名称：

  Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors

  摘要：

  Histone deacetylase (HDAC) inhibitions are known to elicit anticancer effects. We designed and synthesized several HDAC inhibitors. Among these compounds, compound 40 exhibited a more than 10-fold stronger inhibitory activity compared with that of suberoylanilide hydroxamic acid (SAHA) against each human HDAC isozyme in vitro (IC50 values of 40: HDAC1, 0.0038μM; HDAC2, 0.0082μM; HDAC3, 0.015μM; HDAC8, 0.0060μM; HDAC4, 0.058μM; HDAC9, 0.0052μM; HDAC6, 0.058μM). The dose of the administered HDAC inhibitors that contain hydroxamic acid as the zinc-binding group may be reduced by 40. Because the carbostyril subunit is a time-tested structural component of drugs and biologically active compounds, 40 most likely exhibits good absorption, distribution, metabolism, excretion, and toxicity (ADMET). Thus, compound 40 is expected to be a promising therapeutic agent or chemical tool for the investigation of life process.

  DOI：

  10.1016/j.bmc.2014.05.001
• 作为产物：
  描述：

  2-(4-溴苄基)异吲哚啉-1,3-二酮 在 palladium diacetate 、 一水合肼 、 三乙胺 、 N,N-二异丙基乙胺 、 三(邻甲基苯基)磷 、 三氟乙酸 、 丙腈 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.5h， 生成 (E)-3-(4-aminomethylphenyl)acrylic acid ethyl ester
  参考文献：
  名称：

  Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors

  摘要：

  Histone deacetylase (HDAC) inhibitions are known to elicit anticancer effects. We designed and synthesized several HDAC inhibitors. Among these compounds, compound 40 exhibited a more than 10-fold stronger inhibitory activity compared with that of suberoylanilide hydroxamic acid (SAHA) against each human HDAC isozyme in vitro (IC50 values of 40: HDAC1, 0.0038μM; HDAC2, 0.0082μM; HDAC3, 0.015μM; HDAC8, 0.0060μM; HDAC4, 0.058μM; HDAC9, 0.0052μM; HDAC6, 0.058μM). The dose of the administered HDAC inhibitors that contain hydroxamic acid as the zinc-binding group may be reduced by 40. Because the carbostyril subunit is a time-tested structural component of drugs and biologically active compounds, 40 most likely exhibits good absorption, distribution, metabolism, excretion, and toxicity (ADMET). Thus, compound 40 is expected to be a promising therapeutic agent or chemical tool for the investigation of life process.

  DOI：

  10.1016/j.bmc.2014.05.001

文献信息

• [EN] alpha,beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] DERIVES D'ACIDE HYDROXAMIQUE DOLLAR G(A), DOLLAR G(B)-INSATURES ET LEUR UTILISATION COMME INHIBITEURS DE L'HISTONE DESACETYLASE
  申请人：SK CHEMICALS CO LTD

  公开号：WO2003087066A1

  公开（公告）日：2003-10-23

  Disclosed are agents that inhibit histone deacetylase. More specifically, the present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof for anticancer agents or other therapeutic agents based on their histone deacetylase inhibitory activity.

  揭示了抑制组蛋白去乙酰化酶的药剂。更具体地，本发明涉及新型羟基胺基酸衍生物或其药用盐，用作抗癌剂或其他治疗剂，基于它们对组蛋白去乙酰化酶的抑制活性。
• Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
  申请人：Kim Dae-Kee

  公开号：US20050124679A1

  公开（公告）日：2005-06-09

  Disclosed are agents that inhibit histone deacetylase. More specifically, the present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof for anticancer agents or other therapeutic agents based on their histone deacetylase inhibitory activity.

  本发明揭示了一种抑制组蛋白去乙酰化酶的药剂。更具体地说，本发明涉及一种新型的羟酰胺衍生物或其药学上可接受的盐，用作抗癌剂或其他治疗剂，基于它们的组蛋白去乙酰化酶抑制活性。
• US7495022B2
  申请人：——

  公开号：US7495022B2

  公开（公告）日：2009-02-24
• [EN] NOVEL THERAPEUTIC AGENTS<br/>[FR] NOUVEAUX AGENTS THÉRAPEUTIQUES
  申请人：EURO CELTIQUE SA

  公开号：WO2013113841A1

  公开（公告）日：2013-08-08

  The present invention relates to a class of hydroxamic acid compounds of Formula (I), which act as alkylating agents and/or inhibitors of the HDAC pathway, having potential utility in the treatment of a neoplastic disease and immune diseases.
• Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors
  作者：Toshihiko Tashima、Hiroaki Murata、Hidehiko Kodama

  DOI：10.1016/j.bmc.2014.05.001

  日期：2014.7

  Histone deacetylase (HDAC) inhibitions are known to elicit anticancer effects. We designed and synthesized several HDAC inhibitors. Among these compounds, compound 40 exhibited a more than 10-fold stronger inhibitory activity compared with that of suberoylanilide hydroxamic acid (SAHA) against each human HDAC isozyme in vitro (IC50 values of 40: HDAC1, 0.0038μM; HDAC2, 0.0082μM; HDAC3, 0.015μM; HDAC8, 0.0060μM; HDAC4, 0.058μM; HDAC9, 0.0052μM; HDAC6, 0.058μM). The dose of the administered HDAC inhibitors that contain hydroxamic acid as the zinc-binding group may be reduced by 40. Because the carbostyril subunit is a time-tested structural component of drugs and biologically active compounds, 40 most likely exhibits good absorption, distribution, metabolism, excretion, and toxicity (ADMET). Thus, compound 40 is expected to be a promising therapeutic agent or chemical tool for the investigation of life process.